Despite recent advances in understanding the biology of thrombopoiesis, autoimmune thrombocytopenia caused by inhibition of megakaryocytic precursors, remains a treatment dilemma. We report a case of a 43-year-old female who developed amegakaryocytic thrombocytopenia refractory to intravenous immunoglobulin (IVIG), prednisone, cytoxan and vincristine. She was subsequently treated with myeloablative chemotherapy (busulfan and cyclophosphamide) followed by allogeneic bone marrow transplant from a 6/6 HLA-matched sibling. The patient is currently more than 1 year after transplant with complete donor chimerism and restoration of normal thrombopoiesis. A review of the literature shows that the clinical syndrome known as amegakaryocytic thrombocytopenia represents a heterogeneous group of disorders, and clinical experience with immunosuppression varies. Appropriate initial treatment for these patients requires immunosuppressive agents, including antithymocyte globulin (ATG) for steroid refractory disease. However, in the case of symptomatic patients who have an appropriate sibling donor, early hematopoietic progenitor cell transplant, even before administration of ATG, may be necessary. Further studies are needed to better define the pathogenesis and mechanism of this heterogeneous disorder before more definitive treatment algorithms can be established. Keywords: amegakaryocytic thrombocytopenia; allogeneic BMT A 43-year-old female first noted the onset of a petechial rash in August 1996. Laboratory studies performed by her primary care physician revealed a marked thrombocytopenia with platelet count of 36 000/l, a WBC of 6.2 × 10 3 /l, hemoglobin (Hgb) of 11.4 gm/dl, serum B12 level of 328 pg/ml, serum folate of 2.9 ng/ml, and serum ferritin of 9 ng/ml. She was treated with oral iron therapy
and monthly B12 shots without significant improvement in her platelet count.
She was referred to a hematologist in January 1997. At that time the WBC was 6.5 × 10 3 /l, Hgb 12.4 gm/dl, and platelet count, 15 000/l. The peripheral blood smear showed no large platelets, and normal myeloid cells, with no evidence of myelodysplasia. A bone marrow biopsy showed a normocellular marrow, with normal myelopoiesis and erythropoiesis. Also seen were increased numbers of lymphocytes and mast cells, as well as reduced numbers of megakaryocytes. Flow cytometry of the marrow aspirate failed to reveal any clonal lymphocytes or phenotypically abnormal cells in the myeloid or monocyte lineages. A CT scan of the chest/abdomen/pelvis was unrevealing with the exception of a mildly enlarged spleen. Additional studies included a negative rheumatoid factor, ANA, and IgM/IgG antiplatelet antibody tests. Serum protein electrophoresis demonstrated hypogammaglobulinemia without evidence of a paraprotein.
At that time it was felt the history was compatible with an autoimmune thrombocytopenia, and high dose prednisone (100 mg/day) was started. One month later the platelet count was 36 000/l without other substantial changes in the rest of the CBC. She subsequently received 2 days of IVIG at a dose of 1 g/kg each day without improvement in the platelet count. After 4-6 weeks of treatment with prednisone with no improvement in the platelet count, splenectomy was performed in February 1997. Postoperatively, hypertransfusion with platelets raised her platelet count to 100 000/l; the post splenectomy platelet count fell to 65 000/l, and then to 40 000/l (Figure 1) .
In April 1997 she was placed on Danazol (200 mg three times each day), and prednisone was tapered. She was treated again in June 1997 with IVIG (50 g/day × 2 days), without change in the platelet count. She also received three doses of bolus cytoxan (1 g/dose) every 3 weeks followed by two doses of vincristine (2 mg/dose) without significant change in her thrombocytopenia (Figure 1 ). She was then referred to a University Medical Center for further evaluation.
A repeat bone marrow aspirate and biopsy showed no evidence of a clonal population by flow cytometry, and cytogenetic studies were normal. The platelet count varied between 5-10 000/l, and the patient was experiencing easy bruising, gingival bleeding, and diffuse body petechiae. While she initially had appropriate incremental increases to transfused platelets, over the subsequent 8-10 weeks she developed increasing platelet transfusion requirements and diminishing incremental responses to transfused platelets. Upon arrival she was transfused with apheresis platelet products with variable results. HLAmatched platelets were not identified prior to transplant. Repeat examination of the bone marrow showed absence of megakaryocytes, with no evidence of dysplasia in the remaining cell lines and normal cytogenetic studies (Figure 2a) .
The differential diagnosis included myelodysplasia, an aplastic anemia variant, as well as amegakaryocytic thrombocytopenia. Flow cytometry of the marrow aspirate showed no 2N megakaryocytes, and an assay of CFU-Mega revealed absence of megakaryocyte progenitors.
1 Serum thrombopoietin level was measured at 1478 pg/ml (normal range 89-101 pg/ml). 2, 3 This elevation is consistent with previously described thrombopoietin levels seen with acquired amegakaryocytic thrombocytopenia purpura (AATP) and is higher than levels seen in patients with ITP. 4 HLA typing of her sibling showed identity at the HLA-A, -B, and DR loci, and an allogeneic bone marrow transplant (BMT) was proposed with the intent of restoring normal thrombopoiesis. A third bone marrow aspirate was performed which confirmed the previous finding of absent megakaryocytes.
The patient was admitted for allogeneic BMT. The preparative regimen consisted of busulfan 4 mg/kg in divided doses each day for 4 days (16 mg/kg total) followed by 2 days of i.v. cyclophosphamide at a dose of 60 mg/m 2 (120 mg/m 2 total) (BuCy2). She received standard GVHD prophylaxis using tacrolimus and short course methotrexate (15 mg/m 2 day +1, and 10 mg/m 2 on days +3, +6, and +11). She tolerated the immediate post-transplant period well with no febrile neutropenia, and showed signs of neutrophil engraftment on day +10. She was discharged from the hospital for outpatient follow-up with an ANC Ͼ500 on day +13. While she did not achieve platelet engraftment, she did initially achieve sustained neutrophil and erythrocyte engraftment.
Her post-transplant period was complicated by conversion to CMV positivity as measured by PCR amplification of CMV DNA from peripheral blood samples on day +50. She was subsequently treated with intravenous ganciclovir until 3 consecutive weekly PCR tests were negative, for a total treatment duration of 4 weeks. During the treatment period with ganciclovir, her peripheral blood counts began to fall, and by day +81 she was again requiring packed RBC support, continued platelet transfusion support, and had developed leukopenia. She had not achieved platelet engraftment at that time point. A bone marrow examination done on day +81 (after the completion of ganciclovir) showed 50% cellularity, and only one megakaryocyte was noted on the biopsy specimen. Chimerism studies done from the marrow on day +80 revealed 100% donor cells. She continued to have progressive pancytopenia with a bone marrow examination done on day +111 showing 5% cellularity, and sparse hematopoietic material. Again no megakaryocytes were seen. Growth factor support with G-CSF (480 g three times each week) and erythropoietin (30 000 U twice weekly) was initiated in an effort to maintain peripheral counts. Concerns at the time included secondary graft failure, occurrence of an autoimmune pancytopenia, or an infectious/drug effect. Growth factor support was used to stimulate the marrow in an effort to avoid retransplantation. Within 1 week of growth factor initiation, the white blood cell count was within the normal range. Red cell and platelet counts remained low, but the platelet transfusion requirements had significantly decreased. The panel reactive antibody (PRA) 5 (a measure of antibodies to potential platelet donors expressed as a percentage of the tested panel for which pre-existing antibodies are present) declined from over 60% pre-transplant to 0% by day +120. Of note, the decrease in the PRA was paralleled by a decrease in the platelet transfusion requirements.
By day +130, with growth factor support, she was no longer requiring packed RBC support, and platelet transfusions had decreased to once per week. By day +150 her platelet count had risen to 112 000/l, and the G-CSF was stopped. Erythropoietin was stopped on day +170. By day +160 her WBC was 5.7 × 10 3 /l, and the platelet count was 234 000/l. Her last platelet transfusion was day +132, and she had not received packed RBCs for over 40 days (Figure 3) . A bone marrow examination at day +175 revealed hypercellular marrow with adequate megakaryocytes (Figure 2b ). She is currently day +350 after allogeneic BMT with complete hematologic recovery, full donor hematopoiesis, and is no longer receiving immunosuppressive medication.
Discussion
The entity known as acquired amegakaryocytic thrombocytopenia purpura (AATP) was originally postulated to be analogous to acquired pure red cell aplasia in that antibodies against the megakaryocyte (MK) precursor were thought to inhibit MK maturation. [6] [7] [8] Additional theories involved failure of terminal MK differentiation, 9 an intrinsic stem cell defect, an abnormal interaction between CFU-MK and bone marrow stroma, decreased production of a trophic factor (now known as thrombopoietin), or an immunologic attack on the MK or MK progenitor cell. 6 Some investigators have implied that a lack of sensitivity of the CFU-MK to GM-CSF may play a role in the development of AATP. 10 In spite of more recent advances in the understanding of megakaryopoiesis, the identification and development of thrombopoietin and its receptor c-mpl, 11 the conceptual understanding of AATP remains unclear, due in part to the heterogeneous nature of the syndrome.
Immunosuppressive therapy for AATP has included administration of steroids, androgens, cytoxan, anti-thymocyte globulin (ATG), as well as splenectomy, all with varying degrees of success. This is to be contrasted with congenital amegakaryocytic thrombocytopenia for which allogeneic BMT is the treatment of choice. 12 Reviews in the literature have often included a broad spectrum of patients, and it is difficult to define a distinct disease entity from a diverse set of patients. 10, 13 El Saghir et al 14 reported a case which responded to cytoxan, and 2 weeks of prednisone. King et al 15 reported a case which rapidly progressed to aplastic anemia and failed to respond to two cycles of ATG. The literature review by Manoharan et al 16 best exemplifies the dilemma of treating patients with AATP. He reports 28 patients who were treated with numerous regimens, and reports that the patients with the best response were those patients who received active immunosuppressive therapy, especially those who received ATG. However, most of the patients in the series were only treated with either prednisone, androgens, splenectomy, plasmapheresis or some combination of those four interventions. Most of the patients in the series failed to have a response. 16 Charan et al 17 describe two cases of AATP which did not respond to steroids, plasma infusion, and in one case did not respond to plasmapheresis or cyclosporin A therapy. It becomes apparent that all the cases described in the literature are not the same, and that there are cases which respond to prednisone or cytoxan alone, as well as cases which fail to respond to ATG, and thus far there is no clear way to discern which patients require which therapy. Hoffman 7 describes an approach to empiric treatment of AATP based on postulating the mechanism of the thrombocytopenia. In patients with a presumed or measured antibody to CFU-MK, the use of immunosuppression is recommended including steroids, IVIG, cyclophosphamide, and cyclosporine. ATG is reserved for use in patients who have presumed T cell mediated inhibition of megakaryopoiesis of unknown etiology. Other mechanisms of AATP such as HIV-1 infection, ethanol abuse, drug induced AATP, and parvovirus infection are treated with directed specific therapy.
Our patient was initially thought to have an immune mediated thrombocytopenia, and was appropriately treated for such a disorder. The absence of response to standard immunosuppression, and the progression to a condition without megakaryocytes in the bone marrow raised concerns of myelodysplasia and aplastic anemia. A review of the bone marrow morphology showed no evidence of dysplasia, and cytogenetics were repeatedly normal. However, the marrow did show evidence for an absolute lymphocytosis, which may support an immune mechanism for observed thrombocytopenia.
The secondary pancytopenia which began to develop on day +70 was most likely due to the prolonged effect of ganciclovir and CMV on the transplanted marrow. However, there remains the possibility that the secondary pancytopenia may have been due to retained host T cells, or a persistent antibody which was responsible for the initial thrombocytopenia in the first place. Retained host-type T cells would seem less likely as the chimerism studies showed no host cells present on day +80, and the counts increased quite dramatically in response to exogenous cytokines. An additional possibility includes an undocumented viral infection post transplant which caused prolonged marrow suppression and subsequently resolved.
Based on our current case and a review of the literature, there appears to be a great variety in the etiologic mechanisms behind the syndrome described as AATP. In most patients it is reasonable to try empiric therapy with immunosuppressives such as prednisone, cytoxan, vincristine, and IVIG. However, in the case of a young patient with symptomatic thrombocytopenia (as in our case) a trial of ATG may not be possible due to the long period of time needed to see a response from ATG therapy. Additionally there is the risk of further alloimmunization during the time of treatment with ATG. If a suitable matched sibling bone marrow donor can be identified and the patient can tolerate transplant, allogeneic bone marrow transplantation would seem to be the next logical step in the care of a symptomatic patient who has failed initial immunosuppression. If the patient is not symptomatic or a sibling donor is not available, a trial of ATG may be indicated, and in some cases, may produce a complete response. Until the specific site of inhibition to thrombopoiesis can be identified, empiric treatment of this syndrome rather than directed therapy of the disorder will remain the standard of care.
